CIK 0001787306
- Large accelerated filer
Arcutis Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARQT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812974255
- Phone
- +1 805-418-5006
- Business address
- 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
- Former names
- Arcutis, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,253,826
- in 9 filings, $2.1M under 10b5-1 plans
Net −$3,253,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +822 | $6.52 | $5K | 36,029 |
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +1,018 | $7.51 | $8K | 37,047 |
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +2,254 | $8.63 | $19K | 39,301 |
| 2026-11-16 | Welgus Howard G. Director | Sale 10b5-1 | −4,728 | $28.16 | $133K | 34,573 |
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −822 | 4,930 | ||
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −1,018 | 6,108 | ||
| 2026-11-16 | Welgus Howard G. Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −2,254 | 13,524 | ||
| 2026-11-13 | Watanabe Todd | Gift | −144,232 | 568,594 | ||
| 2026-11-04 | Matsuda Masaru EVP, Chief Legal Officer | Exercise or conversion 10b5-1 | +40,000 | $3.64 | $146K | 151,289 |
| 2026-11-04 | Matsuda Masaru EVP, Chief Legal Officer | Sale 10b5-1 | −40,000 | $34.32 | $1.4M | 111,289 |
| 2026-11-04 | Matsuda Masaru EVP, Chief Legal Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −40,000 | 136,000 | ||
| 2026-11-02 | Matsuda Masaru EVP, Chief Legal Officer | Sale 10b5-1 | −1,219 | $31.86 | $39K | 111,289 |
| 2026-11-02 | Burnett Patrick EVP, Chief Medical Officer | Sale | −943 | $31.86 | $30K | 116,649 |
| 2026-11-02 | Watanabe Todd | Sale | −4,377 | $31.86 | $139K | 712,826 |
| 2026-10-23 | SCOTT ROBERT A Director | Grant or award | +2,819 | 2,819 | ||
| 2026-10-23 | SCOTT ROBERT A Director | Grant or award · Stock Option (right to buy) | +20,507 | 20,507 | ||
| 2026-10-23 | SCOTT ROBERT A Director | Grant or award · Stock Option (right to buy) | +8,663 | 8,663 | ||
| 2026-10-15 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +822 | $6.52 | $5K | 36,663 |
| 2026-10-15 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +1,018 | $7.51 | $8K | 37,681 |
| 2026-10-15 | Welgus Howard G. Director | Exercise or conversion 10b5-1 | +2,254 | $8.63 | $19K | 39,935 |
Page 1 of 35 · 689 trades